C21 Investments Reports Strong FY26 Growth Amidst $15M Uncertain Tax Liability

summarizeSummary

C21 Investments announced an 8.3% revenue increase and 13% Adjusted EBITDA growth for fiscal year 2026, demonstrating strong operational performance, but faces a significant $15.1 million uncertain tax liability related to its Section 280E stance, while federal cannabis rescheduling for medical products progresses.

check_boxKey Events · Earnings and Guidance · CXXIF

• Strong Fiscal Year 2026 Operational Performance

  The company reported an 8.3% increase in revenue to $32.6 million, a 13% rise in Adjusted EBITDA to $5.5 million, and a 13% growth in Free Cash Flow to $4.6 million for the fiscal year ended March 31, 2026. Income from operations increased by 78% to $2.3 million, and current liabilities were reduced by $1.6 million.

• Significant Uncertain Tax Position Related to Section 280E

  C21 Investments maintains an uncertain tax position, asserting that Section 280E of the Internal Revenue Code (which disallows business expense deductions for cannabis companies) should not apply to its operations. This position results in a gross unrecognized tax benefits liability of $15.1 million as of March 31, 2026, representing a material financial risk.

• Federal Cannabis Rescheduling Progresses for Medical Products

  The DEA issued rules on April 28, 2026, rescheduling FDA-approved marijuana products and state medical marijuana products from Schedule I to Schedule III. Adult-use cannabis remains Schedule I, with new administrative hearings scheduled for June 29, 2026. The company is assessing the potential impact of these developments on its operations and financial reporting.

• Litigation Settlement Finalized

  The company settled the Eco Firma Farms (EFF) litigation for a total of $2.4 million in cash payments (with $1.1 million already paid) and the issuance of 555,793 common shares on May 27, 2026, resolving a long-standing dispute.

auto_awesomeAnalysis · CXXIF · Life Sciences

C21 Investments reported robust operational performance for fiscal year 2026, with significant increases in revenue, Adjusted EBITDA, and Free Cash Flow, alongside a reduction in current liabilities. This indicates a healthy core business and effective management. However, the company faces a substantial financial risk due to its ongoing challenge to Section 280E of the Internal Revenue Code, resulting in a $15.1 million gross unrecognized tax benefits liability. While the recent DEA rescheduling of medical cannabis to Schedule III is a positive industry development, its direct impact on C21's adult-use operations and the existing 280E liability remains uncertain and represents a major financial overhang. The settlement of a long-standing litigation reduces a source of uncertainty.